Potent and Selective Inhibitors of Human Reticulocyte 12/15-Lipoxygenase as Anti-Stroke Therapies

Citations Over TimeTop 10% of 2014 papers

Abstract

A key challenge facing drug discovery today is variability of the drug target between species, such as with 12/15-lipoxygenase (12/15-LOX), which contributes to ischemic brain injury, but its human and rodent isozymes have different inhibitor specificities. In the current work, we have utilized a quantitative high-throughput (qHTS) screen to identify compound 1 (ML351), a novel chemotype for 12/15-LOX inhibition that has nanomolar potency (IC50 = 200 nM) against human 12/15-LOX and is protective against oxidative glutamate toxicity in mouse neuronal HT22 cells. In addition, it exhibited greater than 250-fold selectivity versus related LOX isozymes, was a mixed inhibitor, and did not reduce the active-site ferric ion. Lastly, 1 significantly reduced infarct size following permanent focal ischemia in a mouse model of ischemic stroke. As such, this represents the first report of a selective inhibitor of human 12/15-LOX with demonstrated in vivo activity in proof-of-concept mouse models of stroke.

Related Papers

• → Neuroprotective Properties of Chitosan and Its Derivatives(2010)165 cited
• → AMP deaminase isozymes in human tissues(1982)131 cited
• → Superoxide Dismutase Isozymes in Different Human Tissues, Their Genetic Control and Intracellular Localization(1973)76 cited
• → Neuroprotective effects of the survival promoting peptide Y-P30(2009)8 cited
• → Organ-specific distribution of isozymes of 5′-nucleotide phosphodiesterase in mouse(1990)4 cited